Hormonal IUD market seen reaching $4.74B by 2030

The hormonal intrauterine devices market is projected to climb from $3.18 billion in 2026 to $4.74 billion by 2030, driven by demand for long-term contraception and growing focus on women’s health. North America leads the market now, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Hormonal IUDs are gaining share as consumers look for long-acting, low-maintenance birth control. - The market outlook points to steady demand tied to reproductive health awareness, menstrual health management and wider access to women’s health care. - Unintended pregnancies remain a core driver of demand for highly effective contraception.

What happened: - The Business Research Company said the global hormonal intrauterine devices market will rise from $2.87 billion in 2025 to $3.18 billion in 2026. - The report projects the market will reach $4.74 billion by 2030. - The forecast implies a 10.6% CAGR from 2025 to 2026 and a 10.5% CAGR through 2030. - North America was the largest regional market in 2025. - Asia-Pacific is forecast to be the fastest-growing region in the coming years. - The company published the forecast in its Hormonal Intrauterine Devices (IUDs) Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035. - A free sample of the market report is available. - The full market report is also available.

The details: - Hormonal IUDs are small, T-shaped plastic devices inserted into the uterus. - The devices release progestin, a synthetic hormone. - The primary contraceptive effect comes from thickening cervical mucus, thinning the uterine lining and sometimes suppressing ovulation. - Hormonal IUDs can also reduce menstrual bleeding and cramps. - Some users stop having periods altogether. - The report cites rising awareness of family planning, broader reproductive healthcare programs, growing preference for long-acting contraceptives, wider availability of hormone-based devices and public health support as past growth drivers. - The report cites non-surgical contraception, menstrual health management, emerging-market access, women’s health technology investment and hormone-delivery innovation as future growth drivers. - The report highlights low-dose hormonal IUDs, long-acting reversible contraceptives, frameless designs, expanded therapeutic uses and greater attention to comfort and safety as key trends. - Hormonal IUDs have failure rates below 1% and can provide protection for 3 to 7 years, depending on the model. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report package includes TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspot infographics, key technology analysis and updated graphics and tables.

Between the lines: - The market forecast suggests contraception is increasingly being treated as a long-duration health product category, not just a one-time device purchase. - The emphasis on low-dose and frameless products points to demand for more user-friendly designs. - The abortion data cited in the report underscores how unmet contraceptive needs continue to shape the market opportunity. - The regional split suggests mature demand in North America and faster adoption potential in developing markets.

What's next: - The market is expected to keep expanding as women’s health spending, device innovation and access improve. - Competition is likely to center on comfort, safety, lower hormone doses and broader therapeutic uses. - Emerging economies may account for a larger share of growth as access to long-acting contraception widens. - The report invites readers to contact the company for more information through its listed sales channels.